Vital Therapies Files Registration Statement With SEC for Proposed Initial Public Offering
SAN DIEGO, CA, Oct 11, 2013 (Marketwired via COMTEX) --
Vital Therapies, Inc., a biotherapeutic company developing a
cell-based therapy targeting the treatment of acute liver failure,
today announced that it has filed a registration statement with the
U.S. Securities and Exchange Commission relating to a proposed
initial public offering of shares of its common stock. The number of
shares to be offered and the price range for the proposed offering
have not yet been determined.
Credit Suisse Securities (USA) LLC and William Blair & Company,
L.L.C. are acting as joint book-running managers for the offering.
Cowen and Company, LLC and Canaccord Genuity Inc. are acting as
co-managers for the offering.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission, but has not yet become
effective. These securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes
The offering will be made only by means of a prospectus. Copies of
the preliminary prospectus relating to the offering may be obtained,
when available, from Credit Suisse Securities (USA) LLC, Attention:
Prospectus Department, One Madison Avenue, New York, NY 10010,
Telephone: (800) 221-1037, Email:
email@example.com; or from William Blair &
Company, L.L.C., Attention: Prospectus Department, 222 West Adams
Street, Chicago, IL 60606, Telephone: (800) 621-0687.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a
cell-based therapy targeting the treatment of acute liver failure.
The company's lead product-candidate, ELAD, is an extracorporeal
bio-artificial liver currently in phase 3 clinical trials. Vital
Therapies, Inc. is based in San Diego, California.
Vital Therapies(R) and ELAD(R) are trademarks of Vital Therapies,
This press release may contain forward-looking statements, including
but not limited to statements regarding Vital Therapies, Inc.'s
proposed initial public offering, and current and future clinical
studies. These statements relate to future events and are subject to
risks, uncertainties and assumptions. These statements are only
predictions based on our current expectations and projections about
future events. You should not place undue reliance on these
statements. Many factors or events may cause our actual results to
differ materially from any forward-looking statement. We do not
undertake to update any forward-looking statements.
Co-Chairman & Chief Executive Officer
Chief Business Officer
Vital Therapies, Inc.
SOURCE: Vital Therapies
[ Back To Technology News's Homepage ]